Mark D. Tyson II, MD, MPH, discusses findings from the phse 3b PATAPSCO study, evaluating durvalumab plus BCG for patients with BCG-naïve, high-risk NMIBC. PATAPSCO was designed as a US-based ...

FDA Breakthrough Device Designation was granted to an AI-powered H&E-based prognostic assay for bladder cancer, described as the first such designation in this disease setting. Proprietary foundation ...

In this video, recorded at the 2026 American Urological Association Annual Meeting in Washington, DC, Murilo De Almeida Luz, MD, gives an overview of the DAROL study design and key findings.

EMBARK enrolled 1068 men with high-risk BCR post-local therapy, conventional-imaging M0 status, PSA ≥1 ng/mL post-prostatectomy or ≥2 ng/mL above post-EBRT nadir, and PSADT ≤9 months. A protocolized ...

Chad A. Reichard, MD, highlights real-world data presented at AUA 2026 on re-induction with nadofaragene firadenovec in patients with BCG-unresponsive non–muscle-invasive bladder cancer. In an ...

Michael S. Cookson, MD, MMHC, FACS, unpacks the significance of the phase 2 ARASEC trial evaluating darolutamide in mHSPC. The novel hybrid design used in the phase 2 ARASEC trial (NCT05059236) 1 —and ...

FDA-cleared total testosterone ChLIA expands an integrated automated workflow that also includes free testosterone and SHBG, supporting multi-analyte androgen evaluation in men and women. The combined ...

ARASEC provides US-based, contemporary evidence supporting darolutamide plus ADT in metastatic hormone-sensitive prostate cancer, demonstrating a 71% reduction in prostate cancer-specific mortality ...

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI ...

A cCR required negative imaging and no viable tumor on re-TURBT, and was achieved in 19/49 patients, with two subsequent intravesical recurrences and no distant failures reported. Twelve-month end ...

Breakthrough Device Designation was granted to a urine-based VOC spectroscopy/ML MCED test targeting prostate, bladder, and kidney cancers, potentially broadening non-blood screening modalities.

New ASCO GU data compares fluorinated PSMA PET tracers, showing how bladder activity affects detection of prostate cancer recurrence at low PSA. In this episode, ‘Comparative PSMA PET Tracer ...